癌癥腫瘤康復-廣東愛硒健康管理有限公司官網帕博利珠單抗對比安慰劑用于IIB期或IIC黑色素瘤輔助治療的無遠處轉移生存期（DMFS）結果：III期KEYNOTE-716 研究
Distant metastasis-free survival with pembrolizumab versus placebo as adjuvant therapy in stage IIB or IIC melanoma: The phase 3 KEYNOTE-716 study.
II期PRADO研究生存結果：在可切除III期黑色素瘤中，伊匹木單抗+納武利尤單抗新輔助治療應答指導的手術治療和新輔助治療的療效
Survival data of PRADO: A phase 2 study of personalized response-driven surgery and adjuvant therapy after neoadjuvant ipilimumab (IPI) and nivolumab (NIVO) in resectable stage III melanoma.
PD-1抑制劑用于可切除促纖維增生性黑色素瘤新輔助治療的療效 (SWOG 1512)
Neoadjuvant PD-1 blockade in patients with resectable desmoplastic melanoma (SWOG 1512).
NeoTrio：一項III期隨機試驗：新輔助帕博利珠單抗序貫或同時達拉非尼+曲美替尼 (D+T) 用于可切除BRAF突變黑色素瘤的療效
NeoTrio: Randomized trial of neoadjuvant (NAT) pembrolizumab (Pembro) alone, in sequence (SEQ) with, or concurrent (CON) with dabrafenib plus trametinib (D+T) in resectable BRAF-mutant stage III melanoma to determine optimal combination of therapy.
納武利尤單抗+relatlimab對比納武利尤單抗用于初治轉移性或不可切除黑色素瘤的療效：RELATIVITY-047研究關鍵亞組的OS和ORR
Nivolumab (NIVO) + relatlimab (RELA) versus NIVO in previously untreated metastatic or unresectable melanoma: OS and ORR by key subgroups from RELATIVITY-047.
阿替利珠單抗+卡比替尼+維莫非尼用于BRAF V600突變陽性黑色素瘤伴中樞神經系統 (CNS) 轉移患者的療效：II期Tricotel研究初步結果
Atezolizumab (A), cobimetinib (C), and vemurafenib (V) in patients (pts) with BRAFV600 mutation–positive melanoma with central nervous system (CNS) metastases (mets): Primary results from phase 2 Tricotel study.
Navtemadlin (KRT-232)用于PD-1/L1抗體治療失敗后TP53野生型 Merkel細胞癌患者的活性
Navtemadlin (KRT-232) activity after failure of anti-PD-1/L1 therapy in patients (pts) with TP53WT Merkel cell carcinoma (MCC).
納武利尤單抗+他克莫司+潑尼松±伊匹木單抗用于腎移植受者晚期皮膚癌的療效
Nivolumab (NIVO) + tacrolimus (TACRO) + prednisone (PRED) +/- ipilimumab (IPI) for kidney transplant recipients (KTR) with advanced cutaneous cancers.
卡瑞利珠單抗（一種靶向PD-1的IgG4單抗）+阿帕替尼（一種 VEGFR-2 TKI）+替莫唑胺用于晚期肢端黑色素瘤一線治療的療效：一項II 期臨床試驗
阿替利珠單抗+貝伐珠單抗治療不可切除或轉移性黏膜黑色素瘤的療效：一項多中心、開放標簽、單臂II期研究
Atezolizumab plus bevacizumab in patients with unresectable or metastatic mucosal melanoma: A multicenter, open-label, single-arm phase 2 study.
LAG-3 抗體 LBL-007+特瑞普利單抗用于不可切除或轉移性黑色素瘤患者的療效：I 期開放標簽、多中心、劑量遞增/擴展研究
Anti-LAG-3 antibody LBL-007 in combination with toripalimab in patients with unresectable or metastatic melanoma: A phase Ⅰ, open-label, multicenter, dose escalation/expansion study.
卡瑞利珠單抗+阿帕替尼治療晚期黏膜黑色素瘤的療效：一項前瞻性單臂研究
Camrelizumab plus apatinib for patients with advanced mucosal melanoma: A prospective single-arm study.
特瑞普利單抗+OrienX010病灶內注射治療Ⅳ期肝轉移黑色素瘤的OS和無復發生存期（RFS）結果：一項Ib期研究
Analysis of overall survival (OS) and relapse-free-survival (RFS) in the phase 1b clinical trial of anti–PD-1 ab (toripalimab) plus intralesional injection of OrienX010 in stage Ⅳ melanoma with liver metastases.
輔助替莫唑胺+順鉑對比高劑量α-2b干擾素治療可切除黏膜黑色素瘤的療效：一項隨機、多中心、III 期對照試驗
Adjuvant temozolomide plus cisplatin versus high-dose interferon alpha-2b in resected mucosal melanoma: A randomized, multicenter, controlled, phase III trial.
肝臟灌注治療葡萄膜黑色素瘤肝轉移的治療，最初來自 III 期隨機對照多中心試驗（SCANDIUM 試驗）
Isolated hepatic perfusion as a treatment for uveal melanoma liver metastases, first results from a phase III randomized controlled multicenter trial (the SCANDIUM trial).
III期FOCUS試驗結果：經皮肝灌注 (PHP) +美法侖治療肝轉移眼部黑色素瘤(PHP-OCM-301/301A)的療效分析
FOCUS phase 3 trial results: Percutaneous hepatic perfusion (PHP) with melphalan for patients with ocular melanoma liver metastases (PHP-OCM-301/301A).
SirTac 試驗第一次中期分析：SIRT+DSM-TACE 用于葡萄膜黑色素瘤肝轉移患者的隨機II期研究
First interim analysis of the SirTac trial: A randomized phase II study of SIRT and DSM-TACE in patients with liver metastases from uveal melanoma.
特瑞普利單抗+阿昔替尼對比特瑞普利單抗或阿西替尼用于初治不可切除或轉移性黏膜黑色素瘤患者的療效：一項隨機、對照、II 期試驗的中期結果
Toripalimab plus axitinib versus toripalimab or axitinib alone in patients with treatment-naive unresectable or metastatic mucosal melanoma: Interim results from a randomized, controlled, phase II trial.
帕博利珠單抗+達拉非尼+曲美替尼治療BRAF V600E/K突變黑色素瘤：KEYNOTE-022 第 1、2 和 3 部分長期隨訪結果
Pembrolizumab (pembro) plus dabrafenib (dab) and trametinib (tram) in BRAFV600E/K-mutant melanoma: Long-term follow-up of KEYNOTE-022 parts 1, 2, and 3.
talimogene laherpare+帕博利珠單抗用于既往PD-1單抗治療進展晚期黑色素瘤患者的初步分析：一項II期、開放標簽、多中心MASTERKEY-115研究
Primary analysis of a phase 2, open-label, multicenter trial of talimogene laherparepvec (T-VEC) plus pembrolizumab (pembro) for the treatment (Tx) of patients (pts) with advanced melanoma (MEL) who progressed on prior anti–PD-1 therapy: MASTERKEY-115.
新輔助免疫治療晚期可切除頭頸部皮膚鱗狀細胞癌 (CSCC-HN) 的結果：一項II期試驗長期隨訪結果
Long-term outcomes of a phase II trial of neoadjuvant immunotherapy for advanced, resectable cutaneous squamous cell carcinoma of the head and neck (CSCC-HN).
免疫治療序貫西妥昔單抗用于局部晚期/轉移性 (LA/M) 皮膚鱗狀細胞癌的療效：I-TACKLE研究
Immunotherapy followed by cetuximab in locally advanced/metastatic (LA/M) cutaneous squamous cell carcinomas (cSCC): The I-TACKLE trial.
加硒教授微信：623296388，送食療電子書，任選一本